Clinicopathologic characteristics and prognosis for male breast cancer compared to female breast cancer

Male breast cancer (MBC) is rare. Due to limited information, MBC has always been understudied. We conducted a retrospective population-based cohort study using data from the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) program. The clinical and biological features of female breast cancer (FBC) patients were compared with MBC patients. Cox regression models and competing risks analyses were used to identify risk factors associated with cancer-related survival in MBC and FBC groups. Results showed that MBC patients suffered from higher TNM stages, tumor grades, and a higher percentage of hormone receptor-positive tumors, compared with FBC patients (all p < 0.05). In addition, the breast tumor locations varied a lot between males and females (p < 0.05). FBC patients were associated with superior overall survival than MBC patients. Results from multivariate cox regression and competing risks analyses showed age, race, T, N, M-stages, tumor grades, estrogen receptor (ER)/progesterone receptor (PR) and human epidermal growth factor receptor-2 (HER-2) overexpression were independent prognosis factors in FBC patients (all p < 0.05). MBC patients had similar risk factors to FBC patients, but PR and HER-2 status did not independently influence survival (all p > 0.05). Tumor location was an independent prognostic factor for both gender groups.

Basic study of a breast cancer epidemiology among the female patients using a regional data source: Case of Chlef region, Algeria

Purpose Breast cancer is a public health problem. It impact given several, important consequences for reducing this disease. We did this study to know the situation of breast cancer and the development of cancer registry. Methods Epidemiological, statistical and computer tools are used to collect, analysis and process of the data, we used the medical records to know the data information on female breast cancer patients, by collaboration with of Bedje Sisters Public Hospitalise of Chlef (BSPHC) and the Oran Cancer Registry. Results We collected approximately 177 cases of female breast cancer, and approximately 601595 female populations during the year 2016 for Chlef region. The incidence rate is more than 29 cases of female breast cancer patients per 100000 female populations for each year. Female breast cancer patients of Chlef region is a major public health problem according to the 2016 study. Incidence rates this disease are greatly increased between 55 years and 75 years old. Conclusion Prevention, early diagnostic and different care and treatment play an important role in reducing this chronic disease in this region and why not over the worldwide?

Global Burden of Female Breast Cancer: Age-period-cohort Analysis of Incidence Trends from 1990 to 2019 and Forecasts for 2035

Background This study aimed to describe the latest epidemiology of female breast cancer globally, analyze the change pattern of the incidence rates and the disease’s association with age, period, and birth cohort, and subsequently present a forecast of breast cancer incidence.Methods Data for analysis were obtained from Global Burden of Disease (GBD) Study 2019 and World Population Prospects 2019 revision by the United Nations (UN). We described the age-standardized incidence rates (ASIRs) from 1990 to 2019 and then calculated the relative risks of period and cohort using an age-period-cohort model, and predicted the trends of ASIRs to 2035.Results In 2019, the global incidence of breast cancer in women increased to 1,977,212 (95% uncertainty interval = 1 807 615 to 2 145 215), with an ASIR of 45.86 (41.91 to 49.76) per 100 000 persons. Among the six selected countries facing burdensome ASIRs, only the USA showed a downward trend from 1990 to 2019, whereas the others showed an increasing or stable trend. The overall net drift was similar in Japan (1.78%), India (1.66%), and Russia (1.27%), reflecting increasing morbidity from 1990 to 2019. The increase in morbidity was particularly striking in China (2.60%) and not significant in Germany (0.42%). The ASIRs were predicted to continue to increase globally, from 45.26 in 2010 to 47.36 in 2035. In most countries and regions, the age specific incidence rate is the highest in those aged over 70 years and will increase in all age groups until 2035. In high-income regions, the age specific incidence rates are expected to decline in women aged over 50 years. Conclusions The global burden of female breast cancer is becoming more serious, especially in developing countries. Raising awareness of the risk factors and prevention strategies for female breast cancer is necessary to reduce future burden.